YC-1 enhances the anti-tumor activity of sorafenib through inhibition of signal transducer and activator of transcription 3 (STAT3) in hepatocellular carcinoma

Hypoxia-mediated sorafenib resistance can be overcome by EF24 through Von Hippel-Lindau tumor suppressor-dependent HIF-1α inhibition in hepatocellular carcinoma

(2013) Yingjian Liang et al.   HEPATOLOGY

Sorafenib and its derivative SC-49 sensitize hepatocellular carcinoma cells to CS-1008, a humanized anti-TNFRSF10B (DR5) antibody

(2012) Kuen-Feng Chen et al.   BRITISH JOURNAL OF PHARMACOLOGY

Molecular mechanisms of sorafenib action in liver cancer cells

(2012) Melchiorre Cervello et al.   CELL CYCLE

Accelerating Cancer Therapy Development: The Importance of Combination Strategies and Collaboration. Summary of an Institute of Medicine Workshop

(2012) P. M. LoRusso et al.   CLINICAL CANCER RESEARCH

Guanylate cyclase activator YC-1 potentiates apoptotic effect of licochalcone A on human epithelial ovarian carcinoma cells via activation of death receptor and mitochondrial pathways

(2012) Chung Soo Lee et al.   EUROPEAN JOURNAL OF PHARMACOLOGY

EGFR activation is a potential determinant of primary resistance of hepatocellular carcinoma cells to sorafenib

(2012) Zakaria Ezzoukhry et al.   INTERNATIONAL JOURNAL OF CANCER

Epidermal growth factor receptor and HER-3 restrict cell response to sorafenib in hepatocellular carcinoma cells

(2012) Marie-José Blivet-Van Eggelpoël et al.   JOURNAL OF HEPATOLOGY

Hepatocellular carcinoma

(2012) Alejandro Forner et al.   LANCET

Insufficient Radiofrequency Ablation Promotes Angiogenesis of Residual Hepatocellular Carcinoma via HIF-1α/VEGFA

(2012) Jian Kong et al.   PLoS One

Cyclic GMP induced apoptosis via protein kinase G in oestrogen receptor-positive and -negative breast cancer cell lines

(2011) Faranak Fallahian et al.   FEBS Journal

p19ARF/p14ARF controls oncogenic functions of signal transducer and activator of transcription 3 in hepatocellular carcinoma

(2011) Doris Schneller et al.   HEPATOLOGY

Signal transducer and activator of transcription 3 is a major kinase-independent target of sorafenib in hepatocellular carcinoma

(2011) Wei-Tien Tai et al.   JOURNAL OF HEPATOLOGY

Effects of YC-1 on Hypoxia-Inducible Factor 1 Alpha in Hypoxic Human Bladder Transitional Carcinoma Cell Line T24 Cells

(2011) Yangle Li et al.   UROLOGIA INTERNATIONALIS

Sorafenib inhibits growth and metastasis of hepatocellular carcinoma by blocking STAT3

(2011) Fang-Ming Gu   WORLD JOURNAL OF GASTROENTEROLOGY

Normoxically Overexpressed Hypoxia Inducible Factor 1-Alpha is Involved in Arsenic Trioxide Resistance Acquisition in Hepatocellular Carcinoma

(2010) Jia-Nien Tung et al.   ANNALS OF SURGICAL ONCOLOGY

Effects of YC-1 targeting hypoxia-inducible factor 1 alpha in oesophageal squamous carcinoma cell line Eca109 cells

(2010) Yadong Feng et al.   CELL BIOLOGY INTERNATIONAL

Sorafenib Overcomes TRAIL Resistance of Hepatocellular Carcinoma Cells through the Inhibition of STAT3

(2010) K.-F. Chen et al.   CLINICAL CANCER RESEARCH

Sorafenib: Where do we go from here?

(2010) Abby B. Siegel et al.   HEPATOLOGY

Vitamin K enhancement of sorafenib-mediated HCC cell growth inhibition in vitro and in vivo

(2010) Gang Wei et al.   INTERNATIONAL JOURNAL OF CANCER

Tyrosine Kinase Inhibitors – A Review on Pharmacology, Metabolism and Side Effects

(2009) Jorg Hartmann et al.   CURRENT DRUG METABOLISM

Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial

(2008) Ann-Lii Cheng et al.   LANCET ONCOLOGY

Sorafenib in Advanced Hepatocellular Carcinoma

(2008) Josep M. Llovet et al.   NEW ENGLAND JOURNAL OF MEDICINE

Anticancer mechanisms of YC-1 in human lung cancer cell line, NCI-H226

(2007) Chun-Jen Chen et al.   BIOCHEMICAL PHARMACOLOGY